Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This case report described a 9-year-old girl initially suspected to have complete androgen insensitivity syndrome, whose laboratory tests later suggested an alternative diagnosis involving atypical steroid metabolism patterns and hormonal responses.

In this laboratory study, finasteride administration in male rats lowered dihydrotestosterone levels and reduced c-Fos protein activation in brain tissue, indicating an impact on brain regions like the hippocampus, though these effects diminished after one month of withdrawing the drug.

This study presents the first report on cloning and characterizing the full-length cDNA of SRD5A1 in Indian catfish (Clarias magur), revealing expression differences across reproductive phases and increased expression post-Ovatide administration in ovaries and testis.

This article from BJU International discusses the slow progress in prostate cancer research and reports no new findings.

This abstract reviews the unclear link between androgenic alopecia and prostate cancer, highlighting the need for further research to determine the mechanisms connecting these two conditions.

This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.

This review discusses the pathways of androgen biosynthesis and reports no new findings, highlighting the need to understand the interplay between the classic and backdoor pathways.

Both drugs lower DHT levels, with GI198745 being more effective.

This review discusses the steroidogenic properties of human skin and suggests that impaired steroidogenesis may be linked to conditions like acne, rosacea, atopic dermatitis, and androgenic alopecia, but reports no new clinical results.

This study showed that Thujae occidentalis semen extract inhibited 5alpha-reductase type 2 in laboratory tests and reduced androgen-related hair loss in animal models, suggesting potential use for male pattern baldness.

This study suggests that 5α-reduced glucocorticoids may have anti-inflammatory potential and could serve as biomarkers for liver inflammation in metabolic disease, with implications for drug development.

This study found that in vitro treatments with 5alpha-reductase inhibitors and androgen receptor antagonists strongly stimulate VEGF expression in dermal papilla cells.

This study found that acute sleep deprivation enhanced 5α-reductase expression and activity in the rat prefrontal cortex, and finasteride treatment reduced associated psychosis- and mania-like behaviors.

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This study found that inhibiting the enzyme 5α-reductase with finasteride counteracted stress-induced prepulse inhibition deficits in socially isolated rats by altering neuroactive steroid concentrations in the brain.

In this study, DHT was observed to have varying effects on hair follicle growth and related protein expression depending on concentration, with the Wnt/β-catenin pathway potentially playing a significant role.

In this study, researchers demonstrated that in a mouse model, the stimulation of mammary tumor growth due to progesterone is primarily caused by its metabolite, 5αP, not progesterone itself.

This study identified significant changes in the expression of nine proteins in the nucleus accumbens of rats treated with finasteride, suggesting potential novel targets for its neuropsychiatric effects.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This study found that inhibiting 5α-reductase in molluscs provokes a specific shell morphology, suggesting gastropods might have unique 5α-reductase substrates absent in vertebrates.

This study found that testosterone may promote glioblastoma progression by being converted into dihydrotestosterone, which enhances cell proliferation, migration, and invasion in GBM cell lines.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.

This study concluded that among men with normal testosterone levels, a small increase in serum dihydrotestosterone may reduce symptoms of hypogonadism, suggesting its potential diagnostic use after ruling out hypogonadism.

This chapter reviews the biosynthesis, mechanism of action, and therapeutic effects of testosterone and related androgens, but reports no new research findings.